Abstract
Chemotherapy is highly effective for treatment of acute lymphoblastic leukemia (ALL). Complete remission rates of > 75% have been achieved with most of the current protocols. Disease related and/or chemotherapy-induced granulocytopenia is the major problem during induction treatment, which may cause lifethreatening infections and will often require dose reductions of the cytostatic agents. Granulocyte colony stimulating factor (G-CSF) enhances the production of neutrophil granulocytes. It has been successfully used to ameliorate chemotherapy-induced granulocytopenia in small-cell lung cancer [1] and in induction chemotherapy in acute non-lymphoblastic leukemia (ANLL) [2]. Since G-CSF does not stimulate the growth of lymphoblasts in vitro it appeared feasible to administer G-CSF concurrently with chemotherapy during induction therapy of ALL.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
